Objective. To determine the serum levels of KL-6, a mucin-like high-molecular-weight glycoprotein, in polymyositis/dermatomyositis (PM/DM ) patients.
KL-6 is a mucin-like high-molecular-weight glycoprotein found in 9-17% of PM/DM patients [11, 12] , and the prognosis of those with ILD is quite poor so that and is classified as 'Cluster 9 (MUC1)' of lung tumour and differentiation antigens according to the findings of approximately 40% of patients with ILD die [11, 12] . ILD is more commonly found in adult PM/DM than immunohistochemical and flow cytometry studies [1] [2] [3] . The molecule consists of multiple heterogeneous subin juvenile PM/DM [12] . In addition, adult PM/DM is associated with various molecules. KL-6 is detected by a murine monoclonal antibody which recognizes a sialylated sugar chain on malignancies, which increase the mortality [12] [13] [14] . Monoclonal antibodies to KL-6 were previously the molecule. It is expressed on alveolar type II pneumocytes and bronchiolar epithelial cells in normal human reported to react strongly to many kinds of malignant tissues, including lung cancer, and the serum levels of lungs, pyloric gland cells in the stomach, epithelial cells in mammary glands and ductal epithelial cells in the KL-6 are elevated in patients with malignant diseases [2] . pancreas.
In fibrosing lung diseases, type II pneumocytes are In the present study, we investigated the serum concentrations of KL-6 in patients with adult PM/DM to regenerated and express KL-6 strongly on the surface [4] . This has also been detected in alveolar macrophages clarify the value of KL-6 in the detection of the severe complication of ILD and associated malignancy. by immunohistochemistry [5] . Serum KL-6 levels have been reported to be elevated in various internal malignancies and benign pulmonary diseases, including interMaterials and methods stitial lung disease ( ILD), hypersensitivity pneumonitis, radiation pneumonia, pulmonary tuberculosis, lung Patients cancer and pulmonary sarcoidosis [2, [5] [6] [7] [8] [9] [10] .
Serum samples were collected from 42 Japanese patients Polymyositis/dermatomyositis (PM/DM ) is an definitively or probably diagnosed as having PM/DM uncommon inflammatory condition involving skeletal according to the criteria of Bohan and Peter [15] sampling. There were three subgroups of PM/DM patients, as defined by the same criteria [15] : primary azide) was added to inhibit the peroxidase reaction. The absorbance at 405 nm was measured. idiopathic DM (30 patients), idiopathic PM (five patients), and DM associated with neoplasia (seven The intra-and interassay coefficients of variation of the kit were under 10%. patients). There were no PM/DM patients who had other collagen diseases, including systemic lupus erythAntinuclear or anticytoplasmic antibodies ematosus, systemic sclerosis or rheumatoid arthritis. Of Antinuclear or anticytoplasmic antibodies were detected the seven patients with DM accompanied by neoplasia, by the indirect immunofluorescence method using two had ovarian carcinoma, two had mammary carcinhuman laryngeal tumour (HEp-2) cells as the substrate oma, two had lung carcinoma, and one had laryngeal [16 ] . The antinuclear or anticytoplasmic antibodies of carcinoma. Five of the seven patients died of metastasis each serum sample were defined as positive when fluorof the cancer. Seventeen of the 35 patients with adult escence was found in the serum diluted at 1:250. PM/DM had ILD, while it was absent in all seven patients with internal malignancy. In this study, no Specific autoantibodies to PM/DM PM/DM patients with internal malignancy showed ILD.
RNA immunoprecipitation, 35S protein immunoElectromyographic examination and skin and muscle precipitation or double immunodiffusion as previously biopsies were performed at the time of diagnosis in all described identified specific autoantibodies to PM/DM, patients. Clinical and laboratory data, including serum including antibodies to anti-tRNA synthetase, antibodcreatine kinase (CK ) levels, erythrocyte sedimentation ies to signal recognition particles, and anti-Ku antibodies rate (ESR) and respiratory function tests, were also and anti-Mi-2 antibodies [17] . obtained at the time of serum sampling. Diagnosis of ILD was made based on the findings of chest radioStatistics graphy, chest computed tomography, lung function tests Values more than twice the standard deviation (..) and diffusing capacity of carbon monoxide (%DLco)
higher than the mean of control values were considered with careful ruling out of differential diagnoses including elevated. The Mann-Whitney U-test assessed the signipneumocystis carinii pneumonia and tuberculosis by ficance of differences and the comparisons of patients' sputum cultures and bronchoalveolar lavage findings.
subgroups were assessed by the x2-test. Spearman's rank No other active lung diseases, including tuberculosis or correlation coefficient assessed correlations with clinical carinii pneumonitis, were found at the time of serum data. Two-tailed P values less than 0.05 were considered sampling among the PM/DM patients. Furthermore, no significant. Data are shown as mean ± standard error patients were treated with drugs that could induce (..). interstitial pneumonitis or have lung toxicity, including bleomycin hydrochloride, pepleomycin sulphate and methotrexate, and were not exposed to silica in their Results disease courses before serum sampling. Control serum Serum levels of KL-6 samples were also obtained from 38 healthy volunteers (18 men and 20 women; age range, 24-70 yr; mean,
The serum KL-6 levels were significantly higher in the 43 yr). There were no significant differences in age and PM/DM patients than in the healthy controls gender distributions between the healthy volunteers and (1183 ± 310 vs 383 ± 9 U/ml; P < 0.01) (Fig. 1) . No the PM/DM patients. All serum samples were stored at correlation was found between serum KL-6 levels and −80°C prior to use.
gender or age distribution in normal control subjects. In 10 patients with PM/DM, we collected serial serum
The cut-off value (mean + 2 ..) was set at 493 U/ml, samples to determine the changes in serum KL-6 levels based on the data from the 38 healthy control sera. in the course of treatments such as corticosteroid Elevated serum KL-6 levels were found in 28 PM/DM therapy, immunosuppressant therapy, or surgical resecpatients (67%). Serum KL-6 levels were elevated in 20 tion of internal malignancies. of the 30 idiopathic DM patients (67%), three of the five patients with idiopathic PM (60%), and five of the Measurement of serum KL-6 levels seven PM/DM patients with neoplasia (71%). There The serum levels of KL-6 were determined using sandwere no significant correlations between the serum KL-6 wich enzyme-linked immunosorbent assay ( ELISA) kits levels and the subsets of PM/DM patients. Elevated using KL-6 antibody, obtained from Eisai Co. Ltd serum KL-6 levels were found in all 17 idiopathic ( Tokyo, Japan), according to the manufacturer's proto-PM/DM patients with ILD, and six of 18 without ILD. col. Briefly, polystyrene cups coated with KL-6 antibody
The sensitivity of serum KL-6 levels for ILD in patients were incubated with 120 ml of 1200-fold diluted serum with adult idiopathic PM/DM was 100% and that for at 25°C for 2 h. Then the cups were washed with 0.9% internal malignancy was 71%. The specificity of serum NaCl and incubated for 1 h with 100 ml of diluted KL-6 levels for internal malignancy or ILD was 67%. horseradish peroxidase-conjugated KL-6 antibody. The
Changes in serum KL-6 levels by therapies cups were then washed again, 100 ml of ABTS solution (2,2∞-azino-bis 3 ethyl-benz-thiazoline-6 sulphonic acid )
In three cases of DM associated with malignancy, the serum KL-6 levels were decreased slightly after surgical and 0.02% H 2 O 2 were added, and incubated at 25°C for 30 min. Finally, 100 ml of stop solution (0.013% sodium resection (cases 1 and 2 in Table 1 ). On the other hand, were found in spite of immunosuppressive therapies for PM/DM (cases 7-10 in Table 1 ).
Correlation of serum KL-6 levels with clinical features and laboratory findings in PM/DM patients
We compared the clinical and laboratory findings of the adult PM/DM patients with their serum KL-6 levels ( Table 2) . No significant differences were found in gender distribution between the patients with elevated serum KL-6 levels and those with normal levels. No correlation was found between age and serum KL-6 levels.
Patients with internal malignancy were excluded from the following analyses between serum KL-6 levels and clinical findings because serum levels of KL-6 were previously reported to be elevated in patients with various kinds of internal malignancies [2] . We found significant correlation between the elevated levels of serum KL-6 and the presence of interstitial pneumonia in patients with idiopathic PM/DM (P < 0.001) by x2 analysis. As for variables associated with interstitial F. 1. Serum KL-6 concentrations ( U/ml ) in 42 PM/DM pneumonia, elevated serum KL-6 levels showed a sigpatients and 38 healthy controls. There were 17 patients with nificant correlation with decreased %DLco (P < 0.001) accompanying interstitial pneumonia (IP) and seven patients by x2 analysis. However, no significant correlations were with internal malignancy. The dashed line represents the cutfound between elevated serum KL-6 levels and decreased off value (mean + 2 ..), which was set at 493 U/ml, based percentage vital capacity (%VC ), probably because on the data for the control sera. The serum KL-6 levels were %VC decreases only in cases with progressed ILD. Spearman's rank correlation coefficient. There were no correlations between elevated serum KL-6 levels and and often induces poor prognosis in spite of therapies.
Case 9 626 731
The initial therapy for PM/DM differs widely depending prognosis. Thus, it is quite important to evaluate the bDied of severe lung fibrosis.
existence and the severity of interstitial pneumonia in treating patients with PM/DM [11, 12] . In general, chest radiography, lung function testing and blood gas anathe serum KL-6 levels were slightly elevated after immunosuppressive therapy for one patient with DM lysis are usually used in the management of ILD in patients with PM/DM. However, these markers can who died of internal malignancy (case 3 in Table 1 ).
In PM/DM patients with ILD, no significant changes often be influenced by other factors, including bacterial or protozoan infections, liver damage by drugs or autoin serum KL-6 levels were observed (cases 4-6 in Table 1 ). no improvement of the ILD was observed in immune hepatitis and muscular involvement. Thus, these variables are not specific, and their range is relatively these patients in spite of immunosuppressive therapies.
In PM/DM patients without ILD or internal malignarrow. Serum levels of KL-6 were previously reported to be nancy, no remarkable changes in serum KL-6 levels T 2. Clinical and laboratory findings of the adult PM/DM patients without internal malignancy (n = 35) with elevated or normal serum KL-6 levels elevated in ILD including hypersensitivity pneumonia, KL-6 levels were useful in the differential diagnosis pneumonitis related to collagen diseases and idiopathic between benign lung diseases and lung carcinoma [2] . interstitial pneumonia [19] . This report showed the In this study, we measured serum KL-6 levels in the elevation of serum KL-6 levels especially in patients seven PM/DM patients with internal malignancy. with active ILD in comparison with patients with inactAlthough interstitial pneumonia was not detected in all ive ILD. Furthermore, the serum KL-6 levels in patients these patients, the serum KL-6 levels of five patients with active ILD were reported to be elevated remarkably were elevated. Additionally, remarkable elevation in comparison with patients with other benign lung (11 300 U/ml ) of the serum KL-6 level was found in a diseases including sarcoidosis or tuberculosis. However, patient with ovarian carcinoma without lung metastasis there was little information about the status of the or interstitial pneumonia. The elevation of serum KL-6 patients in the report. In this study, we compared serum levels in PM/DM patients with various kinds of internal KL-6 levels between 17 PM/DM patients with ILD and malignancy may suggest that KL-6 could be a relatively 18 PM/DM patients without ILD. The strong correlanon-specific tumour marker for various kinds of internal tion between ILD and elevated serum KL-6 levels was malignancy. found. Furthermore, there was a significant inverse There were no significant changes in serum KL-6 correlation between serum KL-6 levels and %VC or levels in longitudinal analysis, probably because of the %DLco. These results suggest that serum KL-6 level small number of cases with successive serum collection. might be a useful marker for ILD in patients with
Further longitudinal studies of serum KL-6 levels before PM/DM. and after the beginning of lung fibrosis in patients with Internal malignancy is another critical complication PM/DM are required to confirm the significance of associated with adult PM/DM [12-14]. KL-6 was serum KL-6 levels. reported to be strongly expressed in various kinds of In summary, the serum KL-6 levels were measured in malignant tissue, including lung adenocarcinoma, lung patients with PM/DM, and the results suggested that squamous cell carcinoma, oesophageal squamous cell KL-6 might be useful in PM/DM patients as an indicacarcinoma, bile ductal adenocarcinoma and pancreas tion of an internal malignancy or the presence of ILD. adenocarcinoma [2] . Furthermore, serum levels of KL-6 were reported to be remarkably elevated in 30-80% of patients with these internal malignancies [2] . The serum levels of KL-6 in patients with internal malignancy were
